KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Recursion Pharmaceuticals (RXRX) Return on Equity (2020 - 2025)

Recursion Pharmaceuticals (RXRX) has disclosed Return on Equity for 6 consecutive years, with 0.59% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Return on Equity changed 0.0% year-over-year to 0.59%, compared with a TTM value of 0.59% through Dec 2025, changed 0.0%, and an annual FY2025 reading of 0.6%, up 2.0% over the prior year.
  • Return on Equity was 0.59% for Q4 2025 at Recursion Pharmaceuticals, up from 0.73% in the prior quarter.
  • Across five years, Return on Equity topped out at 0.44% in Q1 2021 and bottomed at 0.82% in Q1 2024.
  • Average Return on Equity over 5 years is 0.54%, with a median of 0.59% recorded in 2023.
  • The sharpest move saw Return on Equity plummeted -84bps in 2022, then increased 24bps in 2025.
  • Year by year, Return on Equity stood at 0.32% in 2021, then tumbled by -76bps to 0.56% in 2022, then fell by -29bps to 0.73% in 2023, then grew by 18bps to 0.59% in 2024, then rose by 0bps to 0.59% in 2025.
  • Business Quant data shows Return on Equity for RXRX at 0.59% in Q4 2025, 0.73% in Q3 2025, and 0.7% in Q2 2025.